Aspire BioPharma, Inc. is trading 7.8% up at $6.67 on continued high-volatility momentum following a period of recent weakness.
- The stock is extending a sharp rebound after recording double-digit gains on June 15 and June 16.
- No new SEC filings, press releases, or analyst calls have been reported for the company as of June 17, 2026.
- The current price action appears to be driven by market momentum rather than a clearly identified, company-specific news event.